Table 4: Chelation in ASD.

Author Year Type and duration of study Sample size Type of intervention ComparatorsDose Outcome measureFindings Comments

Adams et al. [49]2009Randomized, double blind, placebo controlled, parallel group
Duration: 3 days
(M 69; F 8)
Age: 3–8 years
Each subject was subjected to one round of DMSA to eliminate low metal excretor
Dimercaptosuccinic acid (DMSA) therapy, Completers Placebo, Completers Sic round of DMSA in three daysATEC, PDD-BI, SAS, ADOS, PGINo significant differences between active treatment and controlVery high attrition rate
No power calculation
Not real placebo (each subjects in the placebo group received a round of DMSA)
Multicomponent intervention (patients received before enrollment glutathione)

D. A. Geier and M. R. Geier [50]2006Open label
Duration: minimum 2–maximum 7 months
(M 10; F 1)
Age: 6–14 years
(1) Meso-2,3-dimercaptosuccinic acid
(2) Leuprolide acetate
None(1) 10 mg/kg twice daily
(2) 15 mg every 28 days
ATEC Significant improvement Open label
Small sample size
Multicomponent intervention
Potential conflict of interest

ADOS, Autism Diagnostic Observation Schedule; ATEC, Autism Treatment Evaluation Checklist; ASD, autism spectrum disorder; PDD-BI, Pervasive Developmental Disorder-Behavior Inventory; PGI, Parent Global Impressions; SAS, Severity of Autism Scale.